Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IS5Z
|
|||
| Former ID |
DIB002621
|
|||
| Drug Name |
Anti-CEA designer T cell therapy
|
|||
| Synonyms |
Anti-CEA designer T cells, Beth Israel; Engineered T cells, Harvard/Immunomedics; Anti-CEA designer T cell therapy, Harvard/Immunomedics; Gene therapy (CEA+ adenocarcinoma), Beth Israel; Gene therapy (carcinoembryonic antigen), Harvard/Immunomedics; Gene therapy (CEA+ adenocarcinoma), Harvard/Immunomedics; T cell gene therapy (CEA, colon tumor), Harvard/Immunomedics
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Harvard Medical School
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2nd Generation Anti-CEA Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines and Exhibit Superior Anti-Tumor Activity In Vivo: A Preclinical Evaluation. Clin Cancer Res. 2008 December 15; 14(24): 8112-8122. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.